Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 174

1.

Telacebec (Q203), a New Antituberculosis Agent.

de Jager VR, Dawson R, van Niekerk C, Hutchings J, Kim J, Vanker N, van der Merwe L, Choi J, Nam K, Diacon AH.

N Engl J Med. 2020 Mar 26;382(13):1280-1281. doi: 10.1056/NEJMc1913327. No abstract available.

PMID:
32212527
2.

Reply to: High-dose First-line Treatment Regimen for Recurrent Rifampicin-susceptible Tuberculosis.

Dooley KE, Miyahara S, von Groote-Bidlingmaier F, Sun X, Hafner R, Rosenkranz SL, Ignatius EH, Nuermberger EL, Moran L, Donahue K, Swindells S, Vanker N, Diacon AH.

Am J Respir Crit Care Med. 2020 Mar 4. doi: 10.1164/rccm.202002-0359LE. [Epub ahead of print] No abstract available.

PMID:
32130866
3.

Treatment of Highly Drug-Resistant Pulmonary Tuberculosis.

Conradie F, Diacon AH, Ngubane N, Howell P, Everitt D, Crook AM, Mendel CM, Egizi E, Moreira J, Timm J, McHugh TD, Wills GH, Bateson A, Hunt R, Van Niekerk C, Li M, Olugbosi M, Spigelman M; Nix-TB Trial Team.

N Engl J Med. 2020 Mar 5;382(10):893-902. doi: 10.1056/NEJMoa1901814.

4.

Drug effect of clofazimine on persisters explain an unexpected increase in bacterial load from patients.

Faraj A, Svensson RJ, Diacon AH, Simonsson USH.

Antimicrob Agents Chemother. 2020 Mar 2. pii: AAC.01905-19. doi: 10.1128/AAC.01905-19. [Epub ahead of print]

5.

Xpert MTB/RIF Ultra and Xpert MTB/RIF for diagnosis of tuberculosis in an HIV-endemic setting with a high burden of previous tuberculosis: a two-cohort diagnostic accuracy study.

Mishra H, Reeve BWP, Palmer Z, Caldwell J, Dolby T, Naidoo CC, Jackson JG, Schumacher SG, Denkinger CM, Diacon AH, van Helden PD, Marx FM, Warren RM, Theron G.

Lancet Respir Med. 2020 Feb 14. pii: S2213-2600(19)30370-4. doi: 10.1016/S2213-2600(19)30370-4. [Epub ahead of print]

PMID:
32066534
6.

Fourteen-Day Bactericidal Activity, Safety, and Pharmacokinetics of Linezolid in Adults with Drug-Sensitive Pulmonary Tuberculosis.

Diacon AH, De Jager VR, Dawson R, Narunsky K, Vanker N, Burger DA, Everitt D, Pappas F, Nedelman J, Mendel CM.

Antimicrob Agents Chemother. 2020 Mar 24;64(4). pii: e02012-19. doi: 10.1128/AAC.02012-19. Print 2020 Mar 24.

7.

A Comparative Study of Features for Acoustic Cough Detection Using Deep Architectures.

Miranda IDS, Diacon AH, Niesler TR.

Conf Proc IEEE Eng Med Biol Soc. 2019 Jul;2019:2601-2605. doi: 10.1109/EMBC.2019.8856412.

PMID:
31946429
8.

Early Bactericidal Activity of Different Isoniazid Doses for Drug Resistant TB (INHindsight): A Randomized Open-label Clinical Trial.

Dooley KE, Miyahara S, von Groote-Bidlingmaier F, Sun X, Hafner R, Rosenkranz SL, Ignatius EH, Nuermberger EL, Moran L, Donahue K, Swindells S, Vanker N, Diacon AH; A5312 Study Team.

Am J Respir Crit Care Med. 2020 Jan 16. doi: 10.1164/rccm.201910-1960OC. [Epub ahead of print]

PMID:
31945300
9.

Optimising β-lactams Against Tuberculosis.

de Jager VR, Vanker N, van der Merwe L, van Brakel E, Muliaditan M, Diacon AH.

Am J Respir Crit Care Med. 2020 Jan 10. doi: 10.1164/rccm.201911-2149LE. [Epub ahead of print] No abstract available.

PMID:
31922901
10.

Comparison of isothermal microcalorimetry and BACTEC MGIT960 for the detection of the metabolic activity of Mycobacterium tuberculosis in sputum samples.

Braissant O, Theron G, Friedrich SO, Diacon AH, Bonkat G.

J Appl Microbiol. 2019 Dec 13. doi: 10.1111/jam.14549. [Epub ahead of print]

PMID:
31834654
11.

Bedaquiline, moxifloxacin, pretomanid, and pyrazinamide during the first 8 weeks of treatment of patients with drug-susceptible or drug-resistant pulmonary tuberculosis: a multicentre, open-label, partially randomised, phase 2b trial.

Tweed CD, Dawson R, Burger DA, Conradie A, Crook AM, Mendel CM, Conradie F, Diacon AH, Ntinginya NE, Everitt DE, Haraka F, Li M, van Niekerk CH, Okwera A, Rassool MS, Reither K, Sebe MA, Staples S, Variava E, Spigelman M.

Lancet Respir Med. 2019 Dec;7(12):1048-1058. doi: 10.1016/S2213-2600(19)30366-2. Epub 2019 Nov 12.

12.

New carbon/ZnO/Li2O nanocomposites with enhanced photocatalytic activity.

Diacon A, Mocanu A, Răducanu CE, Busuioc C, Șomoghi R, Trică B, Dinescu A, Rusen E.

Sci Rep. 2019 Nov 14;9(1):16840. doi: 10.1038/s41598-019-53335-7.

13.

Pharmacokinetics of Para-Aminosalicylic Acid and Its 2 Major Metabolites: A Potential Relationship to the Development of Gastrointestinal Intolerance.

Adams KT, Donald PR, Abulfathi AA, Diacon AH, Stander MA, Reuter H.

J Clin Pharmacol. 2020 Apr;60(4):489-494. doi: 10.1002/jcph.1542. Epub 2019 Nov 4.

PMID:
31682027
14.

Final Analysis of a Trial of M72/AS01E Vaccine to Prevent Tuberculosis.

Tait DR, Hatherill M, Van Der Meeren O, Ginsberg AM, Van Brakel E, Salaun B, Scriba TJ, Akite EJ, Ayles HM, Bollaerts A, Demoitié MA, Diacon A, Evans TG, Gillard P, Hellström E, Innes JC, Lempicki M, Malahleha M, Martinson N, Mesia Vela D, Muyoyeta M, Nduba V, Pascal TG, Tameris M, Thienemann F, Wilkinson RJ, Roman F.

N Engl J Med. 2019 Dec 19;381(25):2429-2439. doi: 10.1056/NEJMoa1909953. Epub 2019 Oct 29.

PMID:
31661198
15.

Tuberculous pleural effusion.

Shaw JA, Diacon AH, Koegelenberg CFN.

Respirology. 2019 Oct;24(10):962-971. doi: 10.1111/resp.13673. Epub 2019 Aug 16. Review.

16.

Toxicity related to standard TB therapy for pulmonary tuberculosis and treatment outcomes in the REMoxTB study according to HIV status.

Tweed CD, Crook AM, Dawson R, Diacon AH, McHugh TD, Mendel CM, Meredith SK, Mohapi L, Murphy ME, Nunn AJ, Phillips PPJ, Singh KP, Spigelman M, Gillespie SH.

BMC Pulm Med. 2019 Aug 14;19(1):152. doi: 10.1186/s12890-019-0907-6.

17.

The evaluation of anti-tuberculosis drug effects on phenotypes of Mycobacterium tuberculosis not detected by culture methods.

Kayigire XA, Friedrich SO, van der Merwe L, Diacon AH.

Tuberculosis (Edinb). 2019 May;116:32-34. doi: 10.1016/j.tube.2019.04.001. Epub 2019 Apr 5. No abstract available.

PMID:
31153515
18.

Liquid mycobacterial culture outcomes after different sputum collection techniques before and during treatment.

Lourens M, Philips L, Kleinhans CC, Friedrich SO, Martinson N, Venter A, van der Merwe L, Diacon AH.

Tuberculosis (Edinb). 2019 May;116:17-21. doi: 10.1016/j.tube.2019.03.008. Epub 2019 Mar 28.

PMID:
31153513
19.

Clinical Pharmacokinetics and Pharmacodynamics of Rifampicin in Human Tuberculosis.

Abulfathi AA, Decloedt EH, Svensson EM, Diacon AH, Donald P, Reuter H.

Clin Pharmacokinet. 2019 Sep;58(9):1103-1129. doi: 10.1007/s40262-019-00764-2. Review.

PMID:
31049868
20.

Quantification of viable bacterial load in artificial sputum spiked with Mycobacterium tuberculosis.

Friedrich SO, Kolwijck E, Karinja MN, van der Merwe L, Diacon AH.

Tuberculosis (Edinb). 2019 Mar;115:140-145. doi: 10.1016/j.tube.2019.03.001. Epub 2019 Mar 8.

PMID:
30948169
21.

Prevalence, Predictors, and Successful Treatment Outcomes of Xpert MTB/RIF-identified Rifampicin-resistant Tuberculosis in Post-conflict Eastern Democratic Republic of the Congo, 2012-2017: A Retrospective Province-Wide Cohort Study.

Bulabula ANH, Nelson JA, Musafiri EM, Machekano R, Sam-Agudu NA, Diacon AH, Shah M, Creswell J, Theron G, Warren RM, Jacobson KR, Chirambiza JP, Kalumuna D, Bisimwa BC, Katoto PDMC, Kaswa MK, Birembano FM, Kitete L, Grobusch MP, Kashongwe ZM, Nachega JB.

Clin Infect Dis. 2019 Sep 27;69(8):1278-1287. doi: 10.1093/cid/ciy1105.

22.

Interaction between C-Tb and PPD given concomitantly in a split-body randomised controlled trial.

Aggerbeck H, Ruhwald M, Hoff ST, Tingskov PN, Hellstrom E, Malahleha M, Siebert M, Gani M, Diacon A, Novelijc Z, Andersen P, Dheda K.

Int J Tuberc Lung Dis. 2019 Jan 1;23(1):38-44. doi: 10.5588/ijtld.18.0137. Epub 2018 Dec 20.

PMID:
30572979
23.

Outcomes of midfoot and hindfoot fractures in multitrauma patients.

Diacon AL, Kimmel LA, Hau RC, Gabbe BJ, Edwards ER.

Injury. 2019 Feb;50(2):558-563. doi: 10.1016/j.injury.2018.11.021. Epub 2018 Nov 12.

PMID:
30448328
24.

Phase 2b Controlled Trial of M72/AS01E Vaccine to Prevent Tuberculosis.

Van Der Meeren O, Hatherill M, Nduba V, Wilkinson RJ, Muyoyeta M, Van Brakel E, Ayles HM, Henostroza G, Thienemann F, Scriba TJ, Diacon A, Blatner GL, Demoitié MA, Tameris M, Malahleha M, Innes JC, Hellström E, Martinson N, Singh T, Akite EJ, Khatoon Azam A, Bollaerts A, Ginsberg AM, Evans TG, Gillard P, Tait DR.

N Engl J Med. 2018 Oct 25;379(17):1621-1634. doi: 10.1056/NEJMoa1803484. Epub 2018 Sep 25.

25.

C-Tb skin test to diagnose Mycobacterium tuberculosis infection in children and HIV-infected adults: A phase 3 trial.

Aggerbeck H, Ruhwald M, Hoff ST, Borregaard B, Hellstrom E, Malahleha M, Siebert M, Gani M, Seopela V, Diacon A, Lourens M, Andersen P, Dheda K.

PLoS One. 2018 Sep 24;13(9):e0204554. doi: 10.1371/journal.pone.0204554. eCollection 2018.

26.

Droplets, dust and guinea pigs: an historical review of tuberculosis transmission research, 1878-1940.

Donald PR, Diacon AH, Lange C, Demers AM, von Groote-Bidlingmaier F, Nardell E.

Int J Tuberc Lung Dis. 2018 Sep 1;22(9):972-982. doi: 10.5588/ijtld.18.0173. Review. Erratum in: Int J Tuberc Lung Dis. 2018 Oct 1;22(10):1244.

PMID:
30092861
27.

Increased Doses Lead to Higher Drug Exposures of Levofloxacin for Treatment of Tuberculosis.

Peloquin CA, Phillips PPJ, Mitnick CD, Eisenach K, Patientia RF, Lecca L, Gotuzzo E, Gandhi NR, Butler D, Diacon AH, Martel B, Santillan J, Hunt KR, Vargas D, von Groote-Bidlingmaier F, Seas C, Dianis N, Moreno-Martinez A, Kaur P, Horsburgh CR Jr.

Antimicrob Agents Chemother. 2018 Sep 24;62(10). pii: e00770-18. doi: 10.1128/AAC.00770-18. Print 2018 Oct.

28.

Toxicity associated with tuberculosis chemotherapy in the REMoxTB study.

Tweed CD, Crook AM, Amukoye EI, Dawson R, Diacon AH, Hanekom M, McHugh TD, Mendel CM, Meredith SK, Murphy ME, Murthy SE, Nunn AJ, Phillips PPJ, Singh KP, Spigelman M, Wills GH, Gillespie SH.

BMC Infect Dis. 2018 Jul 11;18(1):317. doi: 10.1186/s12879-018-3230-6.

29.

Relative bioavailability of bedaquiline tablets suspended in water: Implications for dosing in children.

Svensson EM, du Bois J, Kitshoff R, de Jager VR, Wiesner L, Norman J, Nachman S, Smith B, Diacon AH, Hesseling AC, Garcia-Prats AJ.

Br J Clin Pharmacol. 2018 Jun 27. doi: 10.1111/bcp.13696. [Epub ahead of print]

30.

The Potential for Treatment Shortening With Higher Rifampicin Doses: Relating Drug Exposure to Treatment Response in Patients With Pulmonary Tuberculosis.

Svensson EM, Svensson RJ, Te Brake LHM, Boeree MJ, Heinrich N, Konsten S, Churchyard G, Dawson R, Diacon AH, Kibiki GS, Minja LT, Ntingiya NE, Sanne I, Gillespie SH, Hoelscher M, Phillips PPJ, Simonsson USH, Aarnoutse R.

Clin Infect Dis. 2018 Jun 18;67(1):34-41. doi: 10.1093/cid/ciy026.

31.

Perspectives for personalized therapy for patients with multidrug-resistant tuberculosis.

Lange C, Alghamdi WA, Al-Shaer MH, Brighenti S, Diacon AH, DiNardo AR, Grobbel HP, Gröschel MI, von Groote-Bidlingmaier F, Hauptmann M, Heyckendorf J, Köhler N, Kohl TA, Merker M, Niemann S, Peloquin CA, Reimann M, Schaible UE, Schaub D, Schleusener V, Thye T, Schön T.

J Intern Med. 2018 May 28. doi: 10.1111/joim.12780. [Epub ahead of print]

PMID:
29806961
32.

Greater Early Bactericidal Activity at Higher Rifampicin Doses Revealed by Modeling and Clinical Trial Simulations.

Svensson RJ, Svensson EM, Aarnoutse RE, Diacon AH, Dawson R, Gillespie SH, Moodley M, Boeree MJ, Simonsson USH.

J Infect Dis. 2018 Aug 14;218(6):991-999. doi: 10.1093/infdis/jiy242.

PMID:
29718390
33.

Pleural tuberculosis: A concise clinical review.

Shaw JA, Irusen EM, Diacon AH, Koegelenberg CF.

Clin Respir J. 2018 May;12(5):1779-1786. doi: 10.1111/crj.12900. Review.

PMID:
29660258
34.

Liver toxicity associated with tuberculosis chemotherapy in the REMoxTB study.

Tweed CD, Wills GH, Crook AM, Dawson R, Diacon AH, Louw CE, McHugh TD, Mendel C, Meredith S, Mohapi L, Murphy ME, Murray S, Murthy S, Nunn AJ, Phillips PPJ, Singh K, Spigelman M, Gillespie SH.

BMC Med. 2018 Mar 28;16(1):46. doi: 10.1186/s12916-018-1033-7.

35.

Using biomarkers to predict TB treatment duration (Predict TB): a prospective, randomized, noninferiority, treatment shortening clinical trial.

Chen RY, Via LE, Dodd LE, Walzl G, Malherbe ST, Loxton AG, Dawson R, Wilkinson RJ, Thienemann F, Tameris M, Hatherill M, Diacon AH, Liu X, Xing J, Jin X, Ma Z, Pan S, Zhang G, Gao Q, Jiang Q, Zhu H, Liang L, Duan H, Song T, Alland D, Tartakovsky M, Rosenthal A, Whalen C, Duvenhage M, Cai Y, Goldfeder LC, Arora K, Smith B, Winter J, Barry Iii CE; Predict TB Study Group.

Gates Open Res. 2017 Nov 6;1:9. doi: 10.12688/gatesopenres.12750.1.

36.

Erratum for Alsultan et al., "Population Pharmacokinetics of AZD-5847 in Adults with Pulmonary Tuberculosis".

Alsultan A, Furin JJ, Du Bois J, van Brakel E, Chheng P, Venter A, Thiel B, Debanne SA, Boom WH, Diacon AH, Johnson JL, Peloquin CA.

Antimicrob Agents Chemother. 2017 Dec 21;62(1). pii: e02229-17. doi: 10.1128/AAC.02229-17. Print 2018 Jan. No abstract available.

37.

An optimized background regimen design to evaluate the contribution of levofloxacin to multidrug-resistant tuberculosis treatment regimens: study protocol for a randomized controlled trial.

Bouton TC, Phillips PPJ, Mitnick CD, Peloquin CA, Eisenach K, Patientia RF, Lecca L, Gotuzzo E, Gandhi NR, Butler D, Diacon AH, Martel B, Santillan J, Hunt KR, Vargas D, von Groote-Bidlingmaier F, Seas C, Dianis N, Moreno-Martinez A, Horsburgh CR Jr.

Trials. 2017 Nov 25;18(1):563. doi: 10.1186/s13063-017-2292-x.

38.

Supported Cu0 nanoparticles catalyst for controlled radical polymerization reaction and block-copolymer synthesis.

Diacon A, Rusen E, Mocanu A, Nistor LC.

Sci Rep. 2017 Sep 4;7(1):10345. doi: 10.1038/s41598-017-10760-w.

39.

Population Pharmacokinetics of AZD-5847 in Adults with Pulmonary Tuberculosis.

Alsultan A, Furin JJ, Du Bois J, van Brakel E, Chheng P, Venter A, Thiel B, Debanne SA, Boom WH, Diacon AH, Johnson JL, Peloquin CA.

Antimicrob Agents Chemother. 2017 Sep 22;61(10). pii: e01066-17. doi: 10.1128/AAC.01066-17. Print 2017 Oct. Erratum in: Antimicrob Agents Chemother. 2017 Dec 21;62(1):.

40.

A Population Pharmacokinetic Model Incorporating Saturable Pharmacokinetics and Autoinduction for High Rifampicin Doses.

Svensson RJ, Aarnoutse RE, Diacon AH, Dawson R, Gillespie SH, Boeree MJ, Simonsson USH.

Clin Pharmacol Ther. 2018 Apr;103(4):674-683. doi: 10.1002/cpt.778. Epub 2017 Aug 7.

41.

Pulmonary TB: varying radiological presentations in individuals with HIV in Soweto, South Africa.

Kistan J, Laher F, Otwombe K, Panchia R, Mawaka N, Lebina L, Diacon A, Kana B, Martinson N.

Trans R Soc Trop Med Hyg. 2017 Mar 1;111(3):132-136. doi: 10.1093/trstmh/trx028.

42.

Triplicate Sputum Cultures for Efficacy Evaluation of Novel Antituberculosis Regimens.

Diacon AH, van Brakel E, Lounis N, Meyvisch P, Van Baelen B, De Marez T, Jenkins E, Dannemann B.

Am J Respir Crit Care Med. 2017 Dec 15;196(12):1612-1615. doi: 10.1164/rccm.201704-0796LE. No abstract available.

43.

Acquisition of Rifampin Resistance in Pulmonary Tuberculosis.

Kayigire XA, Friedrich SO, van der Merwe L, Diacon AH.

Antimicrob Agents Chemother. 2017 Mar 24;61(4). pii: e02220-16. doi: 10.1128/AAC.02220-16. Print 2017 Apr.

44.

Combating drug-resistant tuberculosis: the unexpected benefits of bedaquiline.

Furin J, Diacon AH, Andries K.

Int J Tuberc Lung Dis. 2017 Jan 1;21(1):4-5. doi: 10.5588/ijtld.16.0768. No abstract available.

PMID:
28157457
45.

Time Trends in Sputum Mycobacterial Load and Two-Day Bactericidal Activity of Isoniazid-Containing Antituberculosis Therapies.

De Jager V, van der Merwe L, Venter A, Donald PR, Diacon AH.

Antimicrob Agents Chemother. 2017 Mar 24;61(4). pii: e02088-16. doi: 10.1128/AAC.02088-16. Print 2017 Apr.

46.

High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial.

Boeree MJ, Heinrich N, Aarnoutse R, Diacon AH, Dawson R, Rehal S, Kibiki GS, Churchyard G, Sanne I, Ntinginya NE, Minja LT, Hunt RD, Charalambous S, Hanekom M, Semvua HH, Mpagama SG, Manyama C, Mtafya B, Reither K, Wallis RS, Venter A, Narunsky K, Mekota A, Henne S, Colbers A, van Balen GP, Gillespie SH, Phillips PPJ, Hoelscher M; PanACEA consortium.

Lancet Infect Dis. 2017 Jan;17(1):39-49. doi: 10.1016/S1473-3099(16)30274-2. Epub 2016 Oct 26.

47.

Serial measurements of transrenal mycobacterial DNA as indicators of the early bactericidal activity (EBA) of antituberculosis drugs.

Heyckendorf J, Labugger I, van der Merwe L, Garcia-Basteiro AL, Diacon AH, Lange C.

Tuberculosis (Edinb). 2017 Jan;102:31-33. doi: 10.1016/j.tube.2016.10.005. Epub 2016 Oct 27. No abstract available.

PMID:
28061950
48.

More on Treatment Outcomes in Multidrug-Resistant Tuberculosis.

Diacon AH, Van Baelen B, Theeuwes M.

N Engl J Med. 2016 Dec 29;375(26):2609-10. No abstract available.

PMID:
28032964
49.

Propidium monoazide and Xpert MTB/RIF to quantify Mycobacterium tuberculosis cells.

Kayigire XA, Friedrich SO, Karinja MN, van der Merwe L, Martinson NA, Diacon AH.

Tuberculosis (Edinb). 2016 Dec;101:79-84. doi: 10.1016/j.tube.2016.08.006. Epub 2016 Sep 4.

PMID:
27865403
50.

Novel facile method for obtaining CdSe/polyaniline/C60 composite materials.

Rusen E, Diacon A, Mocanu A, Nistor LC.

Sci Rep. 2016 Aug 30;6:32237. doi: 10.1038/srep32237.

Supplemental Content

Loading ...
Support Center